PanOptica eyes AMD opportunity with $30M series A round
This article was originally published in Scrip
Executive Summary
Ophthalmology showed that it is still an attractive place for venture capitalists to put their money to work as PanOptica raised $30 million in a series A round led by SV Life Sciences and Third Rock Ventures. Some of the funds were immediately put to use as PanOptica licensed exclusive worldwide rights to PAN-90806, a small molecule selective inhibitor of vascular endothelial growth factor (VEGF) with potential as a topical treatment of neovascular age-related macular degeneration, from OSI Pharmaceuticals, a subsidiary of Astellas.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.